Syphilis kits go under MHRA's (Medicines and Healthcare products Regulatory Agency) evaluation spotlight
This article was originally published in Clinica
Ten syphilis EIAs feature in the second bacteriology kit evaluation report published this year by the Device Evaluation Service (DES) of the UK's Medicines and Healthcare products Regulatory Agency (MHRA). These assays are: Abbott Murex ICE Syphilis; Biokit Bioelisa Syphilis 3.0; biomerieux Trepanostika TP Recombinant; Bio-Rad Syphilis Total; Dade Behring Enzygnost Syphilis; Diesse Enzywell Syphilis; Microgen Bioproducts Mercia Syphilis; Newmarket Laboratories Syphilis EIA II; Omega Pathozyme Syphilis Competition; and Trinity Biotech Captia Syphilis. The report provides a description of the assays, a technical appraisal and details of specificity and sensitivity.
You may also be interested in...
Trade group also compiled website with information and resources to help members "stay up to date and take any necessary steps to mitigate the risks associated with COVID-19." Its members also got a chance to describe potential supply chain disruptions in survey for USDA.
Companies are racing to co-develop coronavirus treatments before finalizing deal teams. These team-ups raise questions about what happens after the pandemic subsides.
Plaintiffs against the prestige, “clinical” skin-care company are targeting anti-aging claims on its Rose Stem Cell Bio-Repair line and statements about hyaluronic acid’s ultra-moisturizing capabilities, used to market its Water Drench range. PTR faces false advertising class actions in California and New York federal courts, and the former case appears to be headed for trial.